Login to Your Account



Financings Roundup

Prosensa Closes $30M Round for Exon-Skipping Drug Pipeline

By Cormac Sheridan
BioWorld Today Correspondent

Thursday, January 26, 2012

Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription